The federal Food and Drug Administration (FDA) held a meeting of its Vaccines and Related Biological Products Advisory Committee on Tuesday to consider recommending the Pfizer COVID-19 vaccine for use in children between 5 and 11 years old. The committee was entrusted with determining if the advantages of the vaccination outweigh the dangers in that age range based on “the totality of the scientific evidence available.”
The committee voted 17-0 to recommend the shot for the age group, with one member abstaining. The proposed dose for younger children is lower than for adults, although the formulation is the same.
The FDA will now make a final ruling shortly in consideration of the recommendation. If the FDA issues final approval for 5 to 11-year-olds, California has already issued a mandate for all children five and older to be vaccinated to attend any school.
One of the committee’s voting members admitted that he was unsure of the extent of long-term risks to younger children from the Pfizer vaccine. He said that “we’re never going to learn about how safe the vaccine is until we start giving it.”
Despite the hazards being unclear, the FDA has stated that they are “clearly outweighed” by the benefits of administering the vaccination to younger children.
As far as benefits are concerned, the Centers for Disease Control and Prevention has reported that out of over 730,000 deaths reported with coronavirus as a cause, 138 have been of children between 5 and 11.
Known risks of the mRNA vaccine types that included the Pfizer product include myocarditis in young adult populations. That risk is highest among male adolescents.
The ongoing government and corporate media assault on anyone who chooses not to receive the vaccine continues unabated. Admissions by government officials that the only way to assess risks is to inject every child in America over five years old is doing very little to alleviate the concerns that parents have about their children’s health.